{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:25:33Z","timestamp":1790796333269,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T00:00:00Z","timestamp":1562371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T00:00:00Z","timestamp":1562371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40801-019-0158-0","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T06:19:31Z","timestamp":1562393971000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice"],"prefix":"10.1007","volume":"6","author":[{"given":"Klaus G.","family":"Parhofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berndt","family":"von Stritzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Dieter","family":"Paar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,6]]},"reference":[{"issue":"29","key":"158_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315\u201381.","journal-title":"Eur Heart J."},{"issue":"14","key":"158_CR2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785\u2013822.","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"158_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5603\/KP.2018.0041","volume":"76","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Kardiol Pol. 2018;76(2):229\u2013313.","journal-title":"Kardiol Pol."},{"key":"158_CR4","doi-asserted-by":"publisher","DOI":"10.4158\/ep161682.cs","author":"American Association of Clinical Endocrinologists, American College of Endocrinology","year":"2017","unstructured":"American Association of Clinical Endocrinologists, American College of Endocrinology. AACE\/ACE comprehensive type 2 diabetes management algorithm 2017. Endocr Pract. 2017. \n                    https:\/\/doi.org\/10.4158\/ep161682.cs\n                    \n                  .","journal-title":"Endocr Pract."},{"issue":"Suppl. 1","key":"158_CR5","first-page":"S1","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of medical care in diabetes: 2018. Diabetes Care. 2018;41(Suppl. 1):S1\u2013159.","journal-title":"Diabetes Care."},{"issue":"14","key":"158_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","volume":"39","author":"U Landmesser","year":"2018","unstructured":"Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Boren J, et al. 2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018;39(14):1131\u201343.","journal-title":"Eur Heart J."},{"key":"158_CR7","unstructured":"Sanofi-Aventis U.S. LLC. Praluent prescribing information (US). 2015. \n                    http:\/\/products.sanofi.us\/praluent\/praluent.pdf\n                    \n                  . [Accessed 8 Aug 2017]."},{"key":"158_CR8","unstructured":"Sanofi-Aventis Groupe. Praluent summary of product characteristics. \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/30956\n                    \n                  . Accessed 2 Jul 2018."},{"key":"158_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","volume":"223","author":"M Farnier","year":"2016","unstructured":"Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials. Int J Cardiol. 2016;223:750\u20137.","journal-title":"Int J Cardiol."},{"issue":"6","key":"158_CR10","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369.","journal-title":"J Clin Lipidol."},{"issue":"1","key":"158_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","volume":"176","author":"EM Roth","year":"2014","unstructured":"Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24\u00a0week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176(1):55\u201361.","journal-title":"Int J Cardiol."},{"key":"158_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","volume":"254","author":"EM Roth","year":"2016","unstructured":"Roth EM, Moriarty PM, Bergeron J, Langslet G, Manvelian G, Zhao J, et al. A phase III randomized trial evaluating alirocumab 300\u00a0mg every 4\u00a0weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis. 2016;254:254\u201362.","journal-title":"Atherosclerosis."},{"issue":"48","key":"158_CR13","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37(48):3588\u201395.","journal-title":"Eur Heart J."},{"issue":"9","key":"158_CR14","doi-asserted-by":"publisher","first-page":"e003421","DOI":"10.1161\/JAHA.116.003421","volume":"5","author":"E Stroes","year":"2016","unstructured":"Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, et al. Efficacy and safety of alirocumab 150\u00a0mg every 4\u00a0weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc. 2016;5(9):e003421.","journal-title":"J Am Heart Assoc."},{"key":"158_CR15","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med."},{"issue":"18","key":"158_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med."},{"key":"158_CR17","unstructured":"Gemainsamer Bundesausschuss. Drug directive\/appendix III: alirocumab. 2016. \n                    https:\/\/www.g-ba.de\/informationen\/beschluesse\/2676\/\n                    \n                  . Accessed 26 Jun 2018."},{"key":"158_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.11.027","volume":"270","author":"RM Stoekenbroek","year":"2018","unstructured":"Stoekenbroek RM, Hartgers ML, Rutte R, de Wijer DD, Stroes ESG, Hovingh GK. PCSK9 inhibitors in clinical practice: delivering on the promise? Atherosclerosis. 2018;270:205\u201310.","journal-title":"Atherosclerosis."},{"key":"158_CR19","first-page":"A16464","volume":"136","author":"T Hollstein","year":"2017","unstructured":"Hollstein T, Grenkowitz T, Spira D, Scharnagl H, M\u00e4rz W, Steinhagen-Thiessen E, et al. Abstract 16464: proprotein convertase subtilisin\/kexin type 9 antibodies (pcsk9-i) treatment of cardiovascular high risk patients in clinical practice: new data regarding safety and effectivity. Circulation. 2017;136:A16464.","journal-title":"Circulation."},{"key":"158_CR20","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/j.atherosclerosis.2017.06.261","volume":"263","author":"E Waldmann","year":"2017","unstructured":"Waldmann E, Bamberger C, Parhofer KG. Statin intolerance is the main indication for PCSK9 inhibition in clinical practice. Atherosclerosis. 2017;263:e80.","journal-title":"Atherosclerosis."},{"key":"158_CR21","unstructured":"Sanofi-Aventis Deutschland GmbH. Prospektive Nicht-Interventionelle Studie zur Erfassung der Wirksamkeit und Vertr\u00e4glichkeit des PCSK9-Inhibitors Alirocumab (Praluent)\u2014PEARL. 2017. \n                    https:\/\/www.pei.de\/SharedDocs\/awb\/nis-0301-0400\/0320.html\n                    \n                  . Accessed 21 Jun 2018."},{"key":"158_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","volume":"278","author":"M Farnier","year":"2018","unstructured":"Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, et al. Long-term safety and efficacy of alirocuamb in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program. Atherosclerosis. 2018;278:307\u201314.","journal-title":"Atherosclerosis."},{"issue":"3","key":"158_CR23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacl.2018.01.013","volume":"12","author":"CJ Glueck","year":"2018","unstructured":"Glueck CJ, Brown A, Goldberg AC, McKenney JM, Kantaros L, Stewart J, et al. Alirocumab in high-risk patients: observations from the open-label expanded use program. J Clin Lipidol. 2018;12(3):662\u20138.","journal-title":"J Clin Lipidol."},{"issue":"11","key":"158_CR24","doi-asserted-by":"publisher","first-page":"e13032","DOI":"10.1111\/ijcp.13032","volume":"71","author":"M Kohli","year":"2017","unstructured":"Kohli M, Patel K, MacMahon Z, Ramachandran R, Crook MA, Reynolds TM, et al. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017;71(11):e13032.","journal-title":"Int J Clin Pract."},{"issue":"2","key":"158_CR25","first-page":"111","volume":"71","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Rev Esp Cardiol (English ed). 2018;71(2):111.","journal-title":"Rev Esp Cardiol (English ed)."},{"issue":"3","key":"158_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s13300-018-0439-8","volume":"9","author":"HN Ginsberg","year":"2018","unstructured":"Ginsberg HN, Farnier M, Robinson JG, Cannon CP, Sattar N, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab in individuals with diabetes mellitus: pooled analyses from five placebo-controlled phase 3 studies. Diabetes Ther. 2018;9(3):1317\u201334.","journal-title":"Diabetes Ther."},{"issue":"12","key":"158_CR27","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/dom.13114","volume":"19","author":"LA Leiter","year":"2017","unstructured":"Leiter LA, Cariou B, Muller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017;19(12):1781\u201392.","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"158_CR28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/dom.13257","volume":"20","author":"KK Ray","year":"2018","unstructured":"Ray KK, Leiter LA, Muller-Wieland D, Cariou B, Colhoun HM, Henry RR, et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018;20(6):1479\u201389.","journal-title":"Diabetes Obes Metab."},{"issue":"39","key":"158_CR29","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","volume":"37","author":"HM Colhoun","year":"2016","unstructured":"Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Muller-Wieland D, Henry RR, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J. 2016;37(39):2981\u20139.","journal-title":"Eur Heart J."},{"issue":"43","key":"158_CR30","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996\u20133003.","journal-title":"Eur Heart J."},{"key":"158_CR31","doi-asserted-by":"crossref","unstructured":"Galema-Boers AMH, Lenzen MJ, Sijbrands EJ, Roeters van Lennep JE. Proprotein convertase subtilisin\/kexin 9 inhibition in patients with familial hypercholesterolemia: initial clinical experience. J Clin Lipidol. 2017;11(3):674\u201381.","DOI":"10.1016\/j.jacl.2017.02.014"},{"issue":"12","key":"158_CR32","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","volume":"118","author":"PH Jones","year":"2016","unstructured":"Jones PH, Bays HE, Chaudhari U, Pordy R, Lorenzato C, Miller K, et al. Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol. 2016;118(12):1805\u201311.","journal-title":"Am J Cardiol."},{"issue":"31\u201332","key":"158_CR33","first-page":"523","volume":"111","author":"G Klose","year":"2014","unstructured":"Klose G, Laufs U, Marz W, Windler E. Familial hypercholesterolemia: developments in diagnosis and treatment. Dtsch Arztebl Int. 2014;111(31\u201332):523\u20139.","journal-title":"Dtsch Arztebl Int."},{"key":"158_CR34","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-019-0158-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-019-0158-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-019-0158-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T23:33:07Z","timestamp":1593905587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-019-0158-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["158"],"URL":"https:\/\/doi.org\/10.1007\/s40801-019-0158-0","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,6]]},"assertion":[{"value":"6 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Sanofi-Aventis Deutschland and funded by Sanofi and Regeneron Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Klaus G. Parhofer has received research support from Regeneron Pharmaceuticals Inc. and Sanofi, has received consulting fees or honoraria from Aegerion, Akcea, Amgen, Ionis, Regeneron Pharmaceuticals, Inc., and Sanofi, and has received fees for participation in review activities from Boehringer-Ingelheim. Berndt von Stritzky, Nicole Pietschmann, Cornelia Dorn, and W. Dieter Paar are employees of and stockholders in Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors contributed to the concept or design of the study, data analysis, or interpretation of data, and critically reviewed and edited the manuscript. All authors approved the final version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}